Alpha Score of 49 reflects weak overall profile with weak momentum, poor value, strong quality, moderate sentiment.
Vertex Pharmaceuticals (VRTX) continues to trade in the upper quartile of its 52-week range of $366.54 to $509.50, reflecting sustained investor interest despite a high valuation profile. The company currently commands a P/E ratio of 46.72, which contrasts with its moderate revenue growth rate of 8.9% year-over-year. While the stock faces pressure from its value sub-score of 16.6, the underlying financial health remains robust. Vertex reports an EPS of 9.51 and a net margin of 32.9%, contributing to a strong quality sub-score of 80.2. This quality metric highlights the company’s operational efficiency and ability to maintain profitability within the healthcare sector. Current momentum sits at 48.3, suggesting a period of consolidation as market participants weigh the premium valuation against the firm’s consistent margin performance. The absence of a sentiment score leaves the stock driven primarily by its fundamental quality and price positioning relative to its annual highs. Investors should monitor upcoming quarterly earnings reports to see if revenue growth accelerates to justify the current earnings multiple.
| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Apr 1, 26 | Liu Joy | EVP and Chief Legal Officer | SELL | 978 | $439K |
| Mar 27, 26 | Bozic Carmen | EVP and CMO | SELL | 2.3K | $1.1M |
| Mar 13, 26 | Bozic Carmen | EVP and CMO | SELL | 2.3K | $1.1M |
| Mar 11, 26 | Mckechnie Duncan | EVP, Chief Commercial Officer | SELL | 2.6K | $1.3M |
| Mar 4, 26 | Mckechnie Duncan | EVP, Chief Commercial Officer | SELL | 2.4K | $1.2M |
| Mar 2, 26 | Liu Joy | EVP and Chief Legal Officer | SELL | 892 | $442K |
| Feb 27, 26 | Kewalramani Reshma | CEO & President | SELL | 400 | $192K |
| Feb 27, 26 | Kewalramani Reshma | CEO & President | SELL | 120 | $58K |
| Feb 27, 26 | Kewalramani Reshma | CEO & President | SELL | 240 | $116K |
| Feb 27, 26 | Kewalramani Reshma | CEO & President | SELL | 2.5K | $1.2M |
| Fund | Shares Held | Position Value | Action (latest Q) |
|---|---|---|---|
| Citadel Ken Griffin | 790K | $358.14M | NEW |
| Renaissance Technologies Jim Simons (founder) | 505K | $228.97M | NEW |
| Marshall Wace | 206K | $93.23M | NEW |
| D.E. Shaw David Shaw | 43K | $19.27M | NEW |
| Point72 Steve Cohen | 28K | $12.74M | NEW |
| ARK Invest Cathie Wood | 26K | $11.83M | NEW |
Vertex Pharmaceuticals Incorporated is a leading biotechnology company founded in 1989 and headquartered in Boston, Massachusetts. It specializes in the discovery, development, and commercialization of transformative therapies, with a primary focus on cystic fibrosis (CF), a life-threatening genetic disease. The company markets a portfolio of CF treatments, including TRIKAFTA/KAFTRIO for patients aged 2 and older with at least one F508del mutation, ALYFTREK for those 6 years and older, SYMDEKO/SYMKEVI and ORKAMBI for patients 6 years and 1 year or older respectively, and KALYDECO for infants as young as 1 month with specific CF mutations. Vertex Pharmaceuticals Incorporated plays a pivotal role in the pharmaceuticals and biotech sector by addressing unmet needs in rare diseases through innovative small-molecule drugs. Its pipeline extends beyond CF into areas like acute and neuropathic pain, with candidates such as VX-548 advancing toward regulatory approval. With trailing twelve-month revenue of approximately $9.72 billion and a market capitalization around $86-101 billion, the company demonstrates significant financial strength and global market presence across multiple exchanges.
Earnings calendar coming soon. Subscribe to get notified when VRTX reports next.
Get earnings alerts →